[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 18 days post-Ivor Lewis esophagectomy with gastric conduit; sudden cough with swallowing, respiratory distress, and sepsis; CT shows a gastric conduit–right mainstem bronchus fistula at the carina with mediastinal air/fluid; bronchoscopy confirms large communication with conduit mucosa visible. This describes an early, major tracheobronchial–gastric conduit fistula causing aspiration and septic contamination of the airway/mediastinum.\\n\\nDefinitive management in this context is urgent operative repair: control of contamination, separation of airway and conduit, vascularized tissue interposition, and often conduit takedown with cervical esophagostomy for delayed reconstruction. Option B explicitly describes emergency right thoracotomy, fistula repair with intercostal muscle flap, and conduit resection with cervical esophagostomy, matching standard thoracic surgical practice.\\n\\nWhy others are worse: A (dual stents) is palliative and has high failure/ongoing sepsis risk in early postoperative large fistula. C (TPN/antibiotics) and D (fibrin glue) are conservative and inappropriate in a septic, large airway fistula. E (conduit abandonment without fistula repair) leaves the bronchial defect untreated, which is not definitive.\\n\\nMinimal fix: Add a brief phrase in the stem indicating the fistula is large with uncontrolled contamination to further justify the need for emergency surgical repair rather than stenting.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 18 days post-Ivor Lewis esophagectomy with gastric conduit; sudden cough with swallowing, respiratory distress, and sepsis; CT shows a gastric conduit–right mainstem bronchus fistula at the carina with mediastinal air/fluid; bronchoscopy confirms large communication with conduit mucosa visible. This describes an early, major tracheobronchial–gastric conduit fistula causing aspiration and septic contamination of the airway/mediastinum.\n\nDefinitive management in this context is urgent operative repair: control of contamination, separation of airway and conduit, vascularized tissue interposition, and often conduit takedown with cervical esophagostomy for delayed reconstruction. Option B explicitly describes emergency right thoracotomy, fistula repair with intercostal muscle flap, and conduit resection with cervical esophagostomy, matching standard thoracic surgical practice.\n\nWhy others are worse: A (dual stents) is palliative and has high failure/ongoing sepsis risk in early postoperative large fistula. C (TPN/antibiotics) and D (fibrin glue) are conservative and inappropriate in a septic, large airway fistula. E (conduit abandonment without fistula repair) leaves the bronchial defect untreated, which is not definitive.\n\nMinimal fix: Add a brief phrase in the stem indicating the fistula is large with uncontrolled contamination to further justify the need for emergency surgical repair rather than stenting.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – best supported answer is B, not C.\\n\\nKey stem clues: 54-year-old with antiphospholipid syndrome (hypercoagulable state); CT shows extensive superior mesenteric and portal venous thrombosis with jejunal pneumatosis and ascites; laparotomy: dusky but viable bowel, no frank necrosis.\\n\\nStandard management for acute mesenteric venous thrombosis with viable bowel is immediate systemic anticoagulation (usually IV unfractionated heparin) and close clinical/surgical monitoring. Catheter-directed thrombolysis is reserved for selected patients with clinical deterioration or failure of anticoagulation, given bleeding risk, need for specialized expertise, and that jejunal pneumatosis alone with viable bowel does not mandate thrombolysis. The stem does not indicate hemodynamic instability, failure of anticoagulation, or contraindication to heparin.\\n\\nOption B (systemic UFH infusion) aligns with guidelines and typical board-level teaching; it also allows easy titration around any subsequent surgery. Options A and E are not standard in acute extensive mesenteric venous thrombosis with viable bowel. Option D uses LMWH instead of UFH perioperatively and unnecessarily mandates second-look. Option C overstates thrombolysis as routine first-line and is not the single best next step.\\n\\nMinimal fix: Change the keyed answer from C to B and revise explanation to emphasize systemic anticoagulation as first-line therapy.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – best supported answer is B, not C.\n\nKey stem clues: 54-year-old with antiphospholipid syndrome (hypercoagulable state); CT shows extensive superior mesenteric and portal venous thrombosis with jejunal pneumatosis and ascites; laparotomy: dusky but viable bowel, no frank necrosis.\n\nStandard management for acute mesenteric venous thrombosis with viable bowel is immediate systemic anticoagulation (usually IV unfractionated heparin) and close clinical/surgical monitoring. Catheter-directed thrombolysis is reserved for selected patients with clinical deterioration or failure of anticoagulation, given bleeding risk, need for specialized expertise, and that jejunal pneumatosis alone with viable bowel does not mandate thrombolysis. The stem does not indicate hemodynamic instability, failure of anticoagulation, or contraindication to heparin.\n\nOption B (systemic UFH infusion) aligns with guidelines and typical board-level teaching; it also allows easy titration around any subsequent surgery. Options A and E are not standard in acute extensive mesenteric venous thrombosis with viable bowel. Option D uses LMWH instead of UFH perioperatively and unnecessarily mandates second-look. Option C overstates thrombolysis as routine first-line and is not the single best next step.\n\nMinimal fix: Change the keyed answer from C to B and revise explanation to emphasize systemic anticoagulation as first-line therapy.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: MEN1 germline mutation; solitary 2.8‑cm duodenal gastrinoma; three regional periduodenal nodal metastases; no pancreatic lesions; biochemical Zollinger–Ellison syndrome. The question asks for optimal surgical management balancing oncologic control and preservation of pancreatic reserve in a MEN1 patient likely to need future pancreatic surgery.\\n\\nMost likely intended management: formal resection of duodenum with regional lymphadenectomy while preserving the pancreas (pancreas‑preserving duodenectomy). This addresses multifocal/lymph‑node–positive duodenal gastrinoma while avoiding the morbidity and long‑term endocrine/exocrine loss of Whipple, which is especially important in MEN1.\\n\\nOption B matches this. Option A (Whipple) is generally considered over-treatment for isolated duodenal disease without pancreatic involvement in MEN1. C (endoscopic resection) is inappropriate given size and nodal disease. D (medical therapy only) ignores resectable, localized gastrinoma with nodal spread. E (simple enucleation) fails to address nodal metastases and the multifocal potential of duodenal gastrinomas.\\n\\nMedical accuracy: The teaching point aligns with contemporary expert consensus for MEN1 duodenal gastrinoma management.\\n\\nMinimal fix: Specify “localized non-metastatic (no liver metastases) disease” in the stem to make clear systemic/palliative therapy is not being considered and to reinforce the curative-intent surgical context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: MEN1 germline mutation; solitary 2.8‑cm duodenal gastrinoma; three regional periduodenal nodal metastases; no pancreatic lesions; biochemical Zollinger–Ellison syndrome. The question asks for optimal surgical management balancing oncologic control and preservation of pancreatic reserve in a MEN1 patient likely to need future pancreatic surgery.\n\nMost likely intended management: formal resection of duodenum with regional lymphadenectomy while preserving the pancreas (pancreas‑preserving duodenectomy). This addresses multifocal/lymph‑node–positive duodenal gastrinoma while avoiding the morbidity and long‑term endocrine/exocrine loss of Whipple, which is especially important in MEN1.\n\nOption B matches this. Option A (Whipple) is generally considered over-treatment for isolated duodenal disease without pancreatic involvement in MEN1. C (endoscopic resection) is inappropriate given size and nodal disease. D (medical therapy only) ignores resectable, localized gastrinoma with nodal spread. E (simple enucleation) fails to address nodal metastases and the multifocal potential of duodenal gastrinomas.\n\nMedical accuracy: The teaching point aligns with contemporary expert consensus for MEN1 duodenal gastrinoma management.\n\nMinimal fix: Specify “localized non-metastatic (no liver metastases) disease” in the stem to make clear systemic/palliative therapy is not being considered and to reinforce the curative-intent surgical context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent completion of FOLFOX (oxaliplatin-based) chemotherapy; rapid onset of painful hepatomegaly, ascites, jaundice, elevated bilirubin and INR; biopsy with sinusoidal congestion and zone 3 hepatocyte necrosis without portal inflammation. This strongly indicates hepatic sinusoidal obstruction syndrome/veno-occlusive disease.\\nDefibrotide is the accepted disease-modifying therapy for moderate–severe sinusoidal obstruction syndrome, supported in post–HSCT and chemotherapy-related cases. It has antithrombotic and profibrinolytic properties without systemic anticoagulation, matching the rationale given.\\nEvaluation of alternatives: High-dose steroids lack evidence for SOS and are not standard of care. TIPS addresses portal hypertension but not the underlying sinusoidal obstruction and can be harmful in diffuse sinusoidal injury; it is not definitive therapy. N-acetylcysteine is indicated for acetaminophen toxicity and some acute liver failure etiologies, not SOS. Urgent transplant evaluation is reserved for fulminant hepatic failure with encephalopathy, not yet described here.\\nMain medical/logical issues: Minor oversimplification (transplant may be needed if progression), but the teaching point and key are sound.\\nMinimal fix: Explicitly state he meets accepted criteria for severe sinusoidal obstruction syndrome to better justify choosing defibrotide as definitive therapy over purely supportive options.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent completion of FOLFOX (oxaliplatin-based) chemotherapy; rapid onset of painful hepatomegaly, ascites, jaundice, elevated bilirubin and INR; biopsy with sinusoidal congestion and zone 3 hepatocyte necrosis without portal inflammation. This strongly indicates hepatic sinusoidal obstruction syndrome/veno-occlusive disease.\nDefibrotide is the accepted disease-modifying therapy for moderate–severe sinusoidal obstruction syndrome, supported in post–HSCT and chemotherapy-related cases. It has antithrombotic and profibrinolytic properties without systemic anticoagulation, matching the rationale given.\nEvaluation of alternatives: High-dose steroids lack evidence for SOS and are not standard of care. TIPS addresses portal hypertension but not the underlying sinusoidal obstruction and can be harmful in diffuse sinusoidal injury; it is not definitive therapy. N-acetylcysteine is indicated for acetaminophen toxicity and some acute liver failure etiologies, not SOS. Urgent transplant evaluation is reserved for fulminant hepatic failure with encephalopathy, not yet described here.\nMain medical/logical issues: Minor oversimplification (transplant may be needed if progression), but the teaching point and key are sound.\nMinimal fix: Explicitly state he meets accepted criteria for severe sinusoidal obstruction syndrome to better justify choosing defibrotide as definitive therapy over purely supportive options.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: CFH p.Arg1215Gln (aHUS risk), recent kidney transplant, POD7 rise in creatinine, thrombocytopenia, schistocytes and hemolysis (TMA), on eculizumab 900 mg weekly started preemptively, platelets normalize by day 10 but creatinine continues to worsen. This suggests post‑transplant aHUS with partial hematologic response but inadequate renal response or possible breakthrough despite C5 blockade.\\n\\nIn current complement inhibitor management, suspected breakthrough aHUS on eculizumab is first evaluated with therapeutic drug monitoring—checking eculizumab trough and CH50 to determine if the issue is subtherapeutic levels/antibody clearance vs pharmacodynamic escape—before changing dose/regimen. Thus option D is best.\\n\\nA: Empiric dose escalation without confirming low trough/active complement is not standard initial step. B: Plasma exchange is not effective in patients adequately treated with C5 inhibitors and is no longer first‑line. C: Switching to ravulizumab similarly requires understanding whether failure is PK/PD; not first step. E: Nephrectomy is last‑resort and not indicated with ongoing treatable TMA.\\n\\nMinimal fix: Clarify in stem that infection, rejection, and obstruction have been excluded to reinforce that TMA/aHUS breakthrough is the working diagnosis guiding drug-level assessment.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: CFH p.Arg1215Gln (aHUS risk), recent kidney transplant, POD7 rise in creatinine, thrombocytopenia, schistocytes and hemolysis (TMA), on eculizumab 900 mg weekly started preemptively, platelets normalize by day 10 but creatinine continues to worsen. This suggests post‑transplant aHUS with partial hematologic response but inadequate renal response or possible breakthrough despite C5 blockade.\n\nIn current complement inhibitor management, suspected breakthrough aHUS on eculizumab is first evaluated with therapeutic drug monitoring—checking eculizumab trough and CH50 to determine if the issue is subtherapeutic levels/antibody clearance vs pharmacodynamic escape—before changing dose/regimen. Thus option D is best.\n\nA: Empiric dose escalation without confirming low trough/active complement is not standard initial step. B: Plasma exchange is not effective in patients adequately treated with C5 inhibitors and is no longer first‑line. C: Switching to ravulizumab similarly requires understanding whether failure is PK/PD; not first step. E: Nephrectomy is last‑resort and not indicated with ongoing treatable TMA.\n\nMinimal fix: Clarify in stem that infection, rejection, and obstruction have been excluded to reinforce that TMA/aHUS breakthrough is the working diagnosis guiding drug-level assessment.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent matched unrelated donor allogeneic HSCT (day +45), new severe hypertension, significant proteinuria, elevated LDH, hemolysis, thrombocytopenia, and only moderately reduced ADAMTS13 activity (45%), with prior tacrolimus exposure. This constellation strongly supports transplant-associated thrombotic microangiopathy (TA-TMA), a complement-mediated process, not classic TTP (which requires severe ADAMTS13 deficiency <10%).\\nThe keyed answer, eculizumab, appropriately targets terminal complement (C5) and is increasingly recognized as effective therapy for high-risk TA-TMA. Stopping calcineurin inhibitors is appropriate; resuming tacrolimus (D) would worsen endothelial injury. Plasma exchange plus steroids (B) is standard for idiopathic TTP but is ineffective in TA-TMA. Rituximab (C) may be adjunctive in TTP or antibody-mediated processes but is not first-line or clearly effective for TA-TMA. Supportive care alone (E) is inadequate for this high-risk presentation.\\nMain medical accuracy issues: The statement that eculizumab is the “only effective therapy” is somewhat overstated but directionally correct for exam purposes. Otherwise medically sound.\\nMinimal fix: Soften explanation wording to “most effective and evidence-supported therapy for high-risk TA-TMA” instead of “only effective therapy.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent matched unrelated donor allogeneic HSCT (day +45), new severe hypertension, significant proteinuria, elevated LDH, hemolysis, thrombocytopenia, and only moderately reduced ADAMTS13 activity (45%), with prior tacrolimus exposure. This constellation strongly supports transplant-associated thrombotic microangiopathy (TA-TMA), a complement-mediated process, not classic TTP (which requires severe ADAMTS13 deficiency <10%).\nThe keyed answer, eculizumab, appropriately targets terminal complement (C5) and is increasingly recognized as effective therapy for high-risk TA-TMA. Stopping calcineurin inhibitors is appropriate; resuming tacrolimus (D) would worsen endothelial injury. Plasma exchange plus steroids (B) is standard for idiopathic TTP but is ineffective in TA-TMA. Rituximab (C) may be adjunctive in TTP or antibody-mediated processes but is not first-line or clearly effective for TA-TMA. Supportive care alone (E) is inadequate for this high-risk presentation.\nMain medical accuracy issues: The statement that eculizumab is the “only effective therapy” is somewhat overstated but directionally correct for exam purposes. Otherwise medically sound.\nMinimal fix: Soften explanation wording to “most effective and evidence-supported therapy for high-risk TA-TMA” instead of “only effective therapy.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14-year-old with genetically confirmed CANDLE syndrome (PSMB8 mutation), chronic atypical neutrophilic dermatosis, lipodystrophy, recurrent fevers, and persistent disease activity despite IL-1 blockade with both anakinra and canakinumab. Question asks for the next therapy. CANDLE is a type I interferonopathy driven by interferon signaling downstream of JAKs; JAK1/2 inhibition (e.g., baricitinib) has emerging evidence of benefit in refractory cases, making baricitinib the single best choice.\\nOther options: High-dose prednisone may palliate but is nonspecific, toxic long term, and not the preferred next-line mechanism-based therapy after IL-1 failure. Tocilizumab (IL-6 blockade) and thalidomide have not shown clear benefit and are considered ineffective. Allogeneic stem cell transplant remains experimental/high risk and is not standard next-line therapy.\\nMain issues: None significant; the stem clearly directs toward targeted interferon-pathway inhibition after IL-1 failure, and the key matches consensus. Medical content is current and accurate for a rare disease, though evidence base is limited.\\nMinimal fix: Add a phrase such as “according to current best available evidence” to acknowledge emerging-data status of JAK inhibition in CANDLE syndrome.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14-year-old with genetically confirmed CANDLE syndrome (PSMB8 mutation), chronic atypical neutrophilic dermatosis, lipodystrophy, recurrent fevers, and persistent disease activity despite IL-1 blockade with both anakinra and canakinumab. Question asks for the next therapy. CANDLE is a type I interferonopathy driven by interferon signaling downstream of JAKs; JAK1/2 inhibition (e.g., baricitinib) has emerging evidence of benefit in refractory cases, making baricitinib the single best choice.\nOther options: High-dose prednisone may palliate but is nonspecific, toxic long term, and not the preferred next-line mechanism-based therapy after IL-1 failure. Tocilizumab (IL-6 blockade) and thalidomide have not shown clear benefit and are considered ineffective. Allogeneic stem cell transplant remains experimental/high risk and is not standard next-line therapy.\nMain issues: None significant; the stem clearly directs toward targeted interferon-pathway inhibition after IL-1 failure, and the key matches consensus. Medical content is current and accurate for a rare disease, though evidence base is limited.\nMinimal fix: Add a phrase such as “according to current best available evidence” to acknowledge emerging-data status of JAK inhibition in CANDLE syndrome.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Vietnamese man; chronic mucocutaneous candidiasis; STAT1 gain-of-function mutation (Th17 defect); disseminated umbilicated papules, hepatosplenomegaly, fevers; biopsy with intracellular yeast with central septation. These strongly indicate disseminated Talaromyces (Penicillium) marneffei infection in an immunodeficient host with a defined STAT1 GOF defect.\\nT. marneffei standard therapy is amphotericin B induction followed by itraconazole maintenance. In STAT1 GOF–associated chronic/refractory fungal infections, JAK inhibition (e.g., ruxolitinib) has emerging evidence to partially reverse the immune defect, making option C a plausible “optimal” regimen that uniquely integrates appropriate antifungal induction/maintenance plus targeted immunomodulation.\\nOther options: A lacks oral step-down and immunologic therapy; B (voriconazole) is not first-line for T. marneffei; D (caspofungin) has poor activity vs this dimorphic fungus; E (fluconazole) is inadequate. Thus C is clearly superior.\\nMedical accuracy: Antifungal strategy is consistent with current standards; ruxolitinib use is based on growing case-series data and is reasonable for a board-level “optimal therapy” framing, though somewhat cutting-edge. No major contradictions.\\nMinimal fix: Clarify organism (e.g., explicitly name Talaromyces marneffei in the stem or biopsy report) to remove any residual diagnostic ambiguity.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Vietnamese man; chronic mucocutaneous candidiasis; STAT1 gain-of-function mutation (Th17 defect); disseminated umbilicated papules, hepatosplenomegaly, fevers; biopsy with intracellular yeast with central septation. These strongly indicate disseminated Talaromyces (Penicillium) marneffei infection in an immunodeficient host with a defined STAT1 GOF defect.\nT. marneffei standard therapy is amphotericin B induction followed by itraconazole maintenance. In STAT1 GOF–associated chronic/refractory fungal infections, JAK inhibition (e.g., ruxolitinib) has emerging evidence to partially reverse the immune defect, making option C a plausible “optimal” regimen that uniquely integrates appropriate antifungal induction/maintenance plus targeted immunomodulation.\nOther options: A lacks oral step-down and immunologic therapy; B (voriconazole) is not first-line for T. marneffei; D (caspofungin) has poor activity vs this dimorphic fungus; E (fluconazole) is inadequate. Thus C is clearly superior.\nMedical accuracy: Antifungal strategy is consistent with current standards; ruxolitinib use is based on growing case-series data and is reasonable for a board-level “optimal therapy” framing, though somewhat cutting-edge. No major contradictions.\nMinimal fix: Clarify organism (e.g., explicitly name Talaromyces marneffei in the stem or biopsy report) to remove any residual diagnostic ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – C is not the best answer.\\n\\nKey stem clues: Dual immune checkpoint therapy (ipilimumab + nivolumab), acute severe fatigue, hypotension, hyponatremia, headache, elevated troponin with preserved EF, and MRI showing diffuse, homogeneously enhancing pituitary enlargement. These findings are classic for immune-related hypophysitis with concurrent immune-related myocarditis. This is a life‑threatening irAE.\\n\\nBest immediate management is high‑dose IV corticosteroids alone (e.g., methylprednisolone 1 mg/kg/day or 1–2 mg/kg/day, or pulse dosing), plus holding immunotherapy; additional steroid‑sparing agents (e.g., mycophenolate) are reserved for steroid‑refractory myocarditis and would not be part of the *immediate* initial step. Thus option A is clearly superior to C for “immediate management.” Option B is incorrect because infliximab is contraindicated in myocarditis. Option D (steroids + ATG) is excessive and nonstandard. Option E (supportive care only) omits mandatory immunosuppression.\\n\\nMain issue: The explanation correctly states mycophenolate is for steroid‑refractory disease but then keys an option that uses it upfront, conflicting with “immediate management.”\\n\\nMinimal fix: Change the keyed answer to A, and revise the explanation to emphasize initial high‑dose IV corticosteroids, reserving mycophenolate for refractory cases.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – C is not the best answer.\n\nKey stem clues: Dual immune checkpoint therapy (ipilimumab + nivolumab), acute severe fatigue, hypotension, hyponatremia, headache, elevated troponin with preserved EF, and MRI showing diffuse, homogeneously enhancing pituitary enlargement. These findings are classic for immune-related hypophysitis with concurrent immune-related myocarditis. This is a life‑threatening irAE.\n\nBest immediate management is high‑dose IV corticosteroids alone (e.g., methylprednisolone 1 mg/kg/day or 1–2 mg/kg/day, or pulse dosing), plus holding immunotherapy; additional steroid‑sparing agents (e.g., mycophenolate) are reserved for steroid‑refractory myocarditis and would not be part of the *immediate* initial step. Thus option A is clearly superior to C for “immediate management.” Option B is incorrect because infliximab is contraindicated in myocarditis. Option D (steroids + ATG) is excessive and nonstandard. Option E (supportive care only) omits mandatory immunosuppression.\n\nMain issue: The explanation correctly states mycophenolate is for steroid‑refractory disease but then keys an option that uses it upfront, conflicting with “immediate management.”\n\nMinimal fix: Change the keyed answer to A, and revise the explanation to emphasize initial high‑dose IV corticosteroids, reserving mycophenolate for refractory cases.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, elevated baseline tryptase (35 ng/mL), documented hereditary alpha-tryptasemia (TPSAB1 copy number gain), persistent symptoms despite maximized H1 blockade (high‑dose cetirizine) and standard‑dose omalizumab. The question asks for the next systemic therapy.\\nChoice D (ketotifen 2 mg BID) is a reasonable next-line mast cell stabilizer when H1 antihistamines and omalizumab are inadequate. It has systemic mast cell–stabilizing and H1‑blocking effects and is used off‑label in mast cell activation syndromes.\\nChoice A (increase omalizumab) lacks strong evidence-based dosing beyond 300 mg q4wk for this indication and is not clearly superior to adding another class. Choice B (chronic prednisone) is inappropriate as prophylaxis due to adverse effects. Choice C (cromolyn sodium) is minimally absorbed and mainly benefits GI symptoms, less appropriate for systemic anaphylaxis. Choice E (allergen immunotherapy) is not targeted to a clearly defined IgE‑mediated trigger.\\nMain medical accuracy: Generally consistent with current understanding of mast cell activation and hereditary alpha‑tryptasemia; minor off‑label nuance but acceptable for exam level.\\nMinimal fix: Clarify in the stem that omalizumab dose has already been optimized at guideline‑supported maximum to reinforce why dose escalation is not preferred.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, elevated baseline tryptase (35 ng/mL), documented hereditary alpha-tryptasemia (TPSAB1 copy number gain), persistent symptoms despite maximized H1 blockade (high‑dose cetirizine) and standard‑dose omalizumab. The question asks for the next systemic therapy.\nChoice D (ketotifen 2 mg BID) is a reasonable next-line mast cell stabilizer when H1 antihistamines and omalizumab are inadequate. It has systemic mast cell–stabilizing and H1‑blocking effects and is used off‑label in mast cell activation syndromes.\nChoice A (increase omalizumab) lacks strong evidence-based dosing beyond 300 mg q4wk for this indication and is not clearly superior to adding another class. Choice B (chronic prednisone) is inappropriate as prophylaxis due to adverse effects. Choice C (cromolyn sodium) is minimally absorbed and mainly benefits GI symptoms, less appropriate for systemic anaphylaxis. Choice E (allergen immunotherapy) is not targeted to a clearly defined IgE‑mediated trigger.\nMain medical accuracy: Generally consistent with current understanding of mast cell activation and hereditary alpha‑tryptasemia; minor off‑label nuance but acceptable for exam level.\nMinimal fix: Clarify in the stem that omalizumab dose has already been optimized at guideline‑supported maximum to reinforce why dose escalation is not preferred.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent bilateral lung transplant (6 hours post-op) for IPF; severe hypoxemia with PaO2/FiO2 85 on 100% FiO2; diffuse bilateral infiltrates on CXR suggesting primary graft dysfunction grade 3; already on inhaled nitric oxide and “optimal ventilator settings,” implying severe isolated respiratory failure without mentioned hemodynamic/cardiac compromise. In this context, full respiratory support with VV-ECMO is indicated. Among VV strategies, dual-lumen right IJ (Avalon-type) cannulation is preferred in modern transplant practice for enabling early mobilization and rehabilitation, consistent with the rationale.\\nOption analysis: A (femoral–jugular VV-ECMO) would provide adequate oxygenation but limits mobility and is therefore inferior as “optimal strategy.” B (VA-ECMO) is excessive and adds cardiac support plus higher complication risk without evidence of cardiac failure. C (ECCO2R at 1 L/min) is inadequate for profound hypoxemia. D (inhaled epoprostenol only) duplicates current vasodilator strategy and ignores need for extracorporeal support.\\nMedical accuracy issues: None substantive; approach is guideline-consistent for severe PGD-3. Minimal fix: Explicitly state hemodynamics and cardiac function are stable to firmly justify excluding VA-ECMO and strengthen the isolated respiratory failure context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent bilateral lung transplant (6 hours post-op) for IPF; severe hypoxemia with PaO2/FiO2 85 on 100% FiO2; diffuse bilateral infiltrates on CXR suggesting primary graft dysfunction grade 3; already on inhaled nitric oxide and “optimal ventilator settings,” implying severe isolated respiratory failure without mentioned hemodynamic/cardiac compromise. In this context, full respiratory support with VV-ECMO is indicated. Among VV strategies, dual-lumen right IJ (Avalon-type) cannulation is preferred in modern transplant practice for enabling early mobilization and rehabilitation, consistent with the rationale.\nOption analysis: A (femoral–jugular VV-ECMO) would provide adequate oxygenation but limits mobility and is therefore inferior as “optimal strategy.” B (VA-ECMO) is excessive and adds cardiac support plus higher complication risk without evidence of cardiac failure. C (ECCO2R at 1 L/min) is inadequate for profound hypoxemia. D (inhaled epoprostenol only) duplicates current vasodilator strategy and ignores need for extracorporeal support.\nMedical accuracy issues: None substantive; approach is guideline-consistent for severe PGD-3. Minimal fix: Explicitly state hemodynamics and cardiac function are stable to firmly justify excluding VA-ECMO and strengthen the isolated respiratory failure context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 5.5‑cm infrarenal AAA (meets size threshold for repair), “thick circumferential rind of periaortic inflammation,” bilateral ureteral obstruction with hydronephrosis, and very elevated ESR/CRP indicate an inflammatory AAA causing extrinsic ureteral compression. Inflammatory AAAs have dense adhesions/periaortitis, making open repair technically difficult with higher morbidity. Initial corticosteroids to reduce inflammation and relieve obstruction before attempting repair is standard; EVAR avoids hostile inflammatory retroperitoneum better than open repair. Thus “Prednisone 40 mg daily for 6 weeks then EVAR” is the most appropriate sequence. \\nOption A/B: immediate repair (open/EVAR) without prior steroid therapy risks complication in active periaortitis and does not address inflammatory component first. Option C: open repair after steroids ignores EVAR’s advantage in severe periaortic inflammation. Option E: prednisone alone leaves a 5.5‑cm aneurysm untreated, risking rupture. No internal contradictions or comparable alternative that rivals D.\\nMedical accuracy issues: Dose/duration of steroids are somewhat arbitrary but within plausible range; overall management logic is consistent with contemporary practice.\\nMinimal fix: Specify that imaging shows features diagnostic of inflammatory AAA and that anatomy is suitable for EVAR to remove ambiguity about repair modality choice.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 5.5‑cm infrarenal AAA (meets size threshold for repair), “thick circumferential rind of periaortic inflammation,” bilateral ureteral obstruction with hydronephrosis, and very elevated ESR/CRP indicate an inflammatory AAA causing extrinsic ureteral compression. Inflammatory AAAs have dense adhesions/periaortitis, making open repair technically difficult with higher morbidity. Initial corticosteroids to reduce inflammation and relieve obstruction before attempting repair is standard; EVAR avoids hostile inflammatory retroperitoneum better than open repair. Thus “Prednisone 40 mg daily for 6 weeks then EVAR” is the most appropriate sequence. \nOption A/B: immediate repair (open/EVAR) without prior steroid therapy risks complication in active periaortitis and does not address inflammatory component first. Option C: open repair after steroids ignores EVAR’s advantage in severe periaortic inflammation. Option E: prednisone alone leaves a 5.5‑cm aneurysm untreated, risking rupture. No internal contradictions or comparable alternative that rivals D.\nMedical accuracy issues: Dose/duration of steroids are somewhat arbitrary but within plausible range; overall management logic is consistent with contemporary practice.\nMinimal fix: Specify that imaging shows features diagnostic of inflammatory AAA and that anatomy is suitable for EVAR to remove ambiguity about repair modality choice.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: Metastatic glucagonoma (diffuse hepatic metastases), functioning tumor (glucagon 2,500 pg/mL, necrolytic migratory erythema, weight loss, new diabetes), Ki‑67 8% (well‑/intermediate‑grade), asking for “first-line therapy.” In contemporary practice, first-line for unresectable/metastatic functional pancreatic NETs includes long-acting somatostatin analogues (octreotide LAR or lanreotide) for symptom control and antiproliferative effect. Evidence base (PROMID and CLARINET) supports both; guidelines typically treat them as equivalent options, chosen by availability/tolerability, not superiority. The stem gives no information (e.g., local formulary, injection route preference) that would privilege lanreotide over octreotide.\\n\\nThus both B and C are equally defensible as first-line. The rationale’s statement that lanreotide is “preferred” purely due to “consistent dosing” is not a widely accepted, guideline-level mandate and is too weak to make B clearly wrong.\\n\\nMedical accuracy: Choice of somatostatin analog and sequence with everolimus/chemotherapy are generally correct; no major pathophysiologic errors. Main issue is overstatement of lanreotide preference.\\n\\nMinimal fix: Explicitly state, e.g., “According to guideline X at this institution, lanreotide is the preferred first-line somatostatin analog,” or re-key to accept either octreotide LAR or lanreotide, or modify options so only one somatostatin analog is listed.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: Metastatic glucagonoma (diffuse hepatic metastases), functioning tumor (glucagon 2,500 pg/mL, necrolytic migratory erythema, weight loss, new diabetes), Ki‑67 8% (well‑/intermediate‑grade), asking for “first-line therapy.” In contemporary practice, first-line for unresectable/metastatic functional pancreatic NETs includes long-acting somatostatin analogues (octreotide LAR or lanreotide) for symptom control and antiproliferative effect. Evidence base (PROMID and CLARINET) supports both; guidelines typically treat them as equivalent options, chosen by availability/tolerability, not superiority. The stem gives no information (e.g., local formulary, injection route preference) that would privilege lanreotide over octreotide.\n\nThus both B and C are equally defensible as first-line. The rationale’s statement that lanreotide is “preferred” purely due to “consistent dosing” is not a widely accepted, guideline-level mandate and is too weak to make B clearly wrong.\n\nMedical accuracy: Choice of somatostatin analog and sequence with everolimus/chemotherapy are generally correct; no major pathophysiologic errors. Main issue is overstatement of lanreotide preference.\n\nMinimal fix: Explicitly state, e.g., “According to guideline X at this institution, lanreotide is the preferred first-line somatostatin analog,” or re-key to accept either octreotide LAR or lanreotide, or modify options so only one somatostatin analog is listed.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 35-year-old woman; chronic iron deficiency anemia; recurrent partial small bowel obstruction; capsule endoscopy with 5 short ulcerated strictures in proximal jejunum; biopsy showing superficial ulceration without granulomas, crypt distortion, or viral inclusions. These favor a diagnosis of cryptogenic multifocal ulcerous stenosing enteritis (CMUSE): multiple short strictures, superficial ulcers, absence of Crohn-type histology, and no clear NSAID history.\\nEvaluation of alternatives: Crohn’s disease (A) typically shows transmural inflammation, granulomas, or chronic architectural distortion, and often longer, segmental disease; anti-TNF is not proven helpful in CMUSE. NSAID enteropathy (B) would require a history of NSAID use, not provided, and CMUSE is a better clinicopathologic fit. Small bowel lymphoma (D) would show mass-like lesions or atypical lymphoid infiltrates, not just superficial ulcers. Refractory celiac disease (E) requires prior celiac diagnosis, villous atrophy, and serologic context, none of which is given. Budesonide is described in the explanation as effective for CMUSE, and the other treatments are inappropriate for the presented pathology. No internal contradictions or missing critical data prevent a single best choice.\\nMinimal fix: Explicitly state absence of NSAID use and prior negative evaluation for celiac disease to reinforce exclusion diagnoses.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 35-year-old woman; chronic iron deficiency anemia; recurrent partial small bowel obstruction; capsule endoscopy with 5 short ulcerated strictures in proximal jejunum; biopsy showing superficial ulceration without granulomas, crypt distortion, or viral inclusions. These favor a diagnosis of cryptogenic multifocal ulcerous stenosing enteritis (CMUSE): multiple short strictures, superficial ulcers, absence of Crohn-type histology, and no clear NSAID history.\nEvaluation of alternatives: Crohn’s disease (A) typically shows transmural inflammation, granulomas, or chronic architectural distortion, and often longer, segmental disease; anti-TNF is not proven helpful in CMUSE. NSAID enteropathy (B) would require a history of NSAID use, not provided, and CMUSE is a better clinicopathologic fit. Small bowel lymphoma (D) would show mass-like lesions or atypical lymphoid infiltrates, not just superficial ulcers. Refractory celiac disease (E) requires prior celiac diagnosis, villous atrophy, and serologic context, none of which is given. Budesonide is described in the explanation as effective for CMUSE, and the other treatments are inappropriate for the presented pathology. No internal contradictions or missing critical data prevent a single best choice.\nMinimal fix: Explicitly state absence of NSAID use and prior negative evaluation for celiac disease to reinforce exclusion diagnoses.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-term tenofovir DF use, proximal muscle weakness, bone pain, hypophosphatemia, phosphaturia, glucosuria with normal serum glucose, and metabolic acidosis clearly indicate a proximal (Fanconi) renal tubular acidosis secondary to tenofovir-induced Fanconi syndrome. This causes urinary wasting of phosphate and bicarbonate, leading to osteomalacia and acidosis.\\nThe question asks for the optimal electrolyte replacement regimen. Management requires correction of both phosphate depletion and bicarbonate loss. Option D (oral sodium phosphate plus sodium bicarbonate 650 mg TID) directly addresses both abnormalities and is therefore the most appropriate.\\nOption A replaces phosphate but ignores bicarbonate loss and acidosis. Option B adds calcitriol unnecessarily in the absence of evidence for vitamin D deficiency; Fanconi osteomalacia is primarily from phosphate wasting. Option C (IV phosphate bolus) is excessive for a stable outpatient with chronic loss and risks complications. Option E (stop tenofovir only) fails to treat marked existing electrolyte depletion.\\nMain medical accuracy issues: minor—guideline details (exact phosphate/bicarbonate doses) can vary, but the therapeutic principle is sound.\\nMinimal fix: Specify severity/clinical stability (e.g., “hemodynamically stable outpatient”) to justify choosing oral over IV replacement more clearly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-term tenofovir DF use, proximal muscle weakness, bone pain, hypophosphatemia, phosphaturia, glucosuria with normal serum glucose, and metabolic acidosis clearly indicate a proximal (Fanconi) renal tubular acidosis secondary to tenofovir-induced Fanconi syndrome. This causes urinary wasting of phosphate and bicarbonate, leading to osteomalacia and acidosis.\nThe question asks for the optimal electrolyte replacement regimen. Management requires correction of both phosphate depletion and bicarbonate loss. Option D (oral sodium phosphate plus sodium bicarbonate 650 mg TID) directly addresses both abnormalities and is therefore the most appropriate.\nOption A replaces phosphate but ignores bicarbonate loss and acidosis. Option B adds calcitriol unnecessarily in the absence of evidence for vitamin D deficiency; Fanconi osteomalacia is primarily from phosphate wasting. Option C (IV phosphate bolus) is excessive for a stable outpatient with chronic loss and risks complications. Option E (stop tenofovir only) fails to treat marked existing electrolyte depletion.\nMain medical accuracy issues: minor—guideline details (exact phosphate/bicarbonate doses) can vary, but the therapeutic principle is sound.\nMinimal fix: Specify severity/clinical stability (e.g., “hemodynamically stable outpatient”) to justify choosing oral over IV replacement more clearly.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 70-year-old man, coronary artery disease, incidentally found clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation, VAF 12%, normal CBC, no splenomegaly, asking specifically for annual thrombosis risk and recommended prophylaxis. JAK2-positive CHIP is associated with increased arterial thrombosis risk (on the order of ~0.5–1% per year above baseline), and low-dose aspirin is commonly recommended as primary prophylaxis, particularly in patients with cardiovascular comorbidities; cytoreductive therapy such as hydroxyurea is reserved for overt myeloproliferative neoplasms, not isolated CHIP.\\nOption C (0.5% annual thrombosis risk; start low-dose aspirin) correctly captures both the approximate magnitude of risk and appropriate management. Other options are incorrect due to under- or overestimating risk and/or recommending no prophylaxis, cytoreduction, or full-dose anticoagulation, which are not standard for asymptomatic CHIP with normal counts. No major logical inconsistencies or significant medical inaccuracies are evident.\\nMinimal fix: Clarify in the stem that evidence supports low-dose aspirin in JAK2-mutant CHIP with cardiovascular disease, to make the management rationale explicit and reduce ambiguity around practice variation.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 70-year-old man, coronary artery disease, incidentally found clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation, VAF 12%, normal CBC, no splenomegaly, asking specifically for annual thrombosis risk and recommended prophylaxis. JAK2-positive CHIP is associated with increased arterial thrombosis risk (on the order of ~0.5–1% per year above baseline), and low-dose aspirin is commonly recommended as primary prophylaxis, particularly in patients with cardiovascular comorbidities; cytoreductive therapy such as hydroxyurea is reserved for overt myeloproliferative neoplasms, not isolated CHIP.\nOption C (0.5% annual thrombosis risk; start low-dose aspirin) correctly captures both the approximate magnitude of risk and appropriate management. Other options are incorrect due to under- or overestimating risk and/or recommending no prophylaxis, cytoreduction, or full-dose anticoagulation, which are not standard for asymptomatic CHIP with normal counts. No major logical inconsistencies or significant medical inaccuracies are evident.\nMinimal fix: Clarify in the stem that evidence supports low-dose aspirin in JAK2-mutant CHIP with cardiovascular disease, to make the management rationale explicit and reduce ambiguity around practice variation.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: young adult with documented C1q deficiency (classical complement pathway defect), recurrent sinopulmonary infections with S. pneumoniae, SLE-like disease. The question asks for “recommended infection prophylaxis.” In complement (especially terminal) deficiencies, vaccination against encapsulated bacteria is standard; antibiotic prophylaxis is sometimes recommended but practice varies and is clearer for asplenia and sickle cell disease than for isolated early complement deficiencies.\\n\\nLogical issues: The stem provides no guideline context or severity details (e.g., history of invasive pneumococcal disease, local standard of care) to justify lifelong penicillin vs vaccine-based prevention. Both lifelong penicillin (A) and focused immunization (E) are plausible strategies; some authorities would prioritize vaccination +/- booster schedules over routine continuous antibiotics, so the single “best” answer is not clearly forced by the vignette. Thus the keyed answer relies on an unstated assumption that lifelong penicillin is standard of care in isolated C1q deficiency.\\n\\nMedical accuracy: The pathophysiologic explanation is correct, but the statement that “lifelong penicillin prophylaxis is recommended” is stronger than typical guideline language and may not be universally accepted.\\n\\nMinimal fix: Explicitly state that current institutional/consensus guidelines in this scenario recommend lifelong penicillin prophylaxis in addition to standard vaccination, or change the options so only one reasonable prophylactic approach remains.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: young adult with documented C1q deficiency (classical complement pathway defect), recurrent sinopulmonary infections with S. pneumoniae, SLE-like disease. The question asks for “recommended infection prophylaxis.” In complement (especially terminal) deficiencies, vaccination against encapsulated bacteria is standard; antibiotic prophylaxis is sometimes recommended but practice varies and is clearer for asplenia and sickle cell disease than for isolated early complement deficiencies.\n\nLogical issues: The stem provides no guideline context or severity details (e.g., history of invasive pneumococcal disease, local standard of care) to justify lifelong penicillin vs vaccine-based prevention. Both lifelong penicillin (A) and focused immunization (E) are plausible strategies; some authorities would prioritize vaccination +/- booster schedules over routine continuous antibiotics, so the single “best” answer is not clearly forced by the vignette. Thus the keyed answer relies on an unstated assumption that lifelong penicillin is standard of care in isolated C1q deficiency.\n\nMedical accuracy: The pathophysiologic explanation is correct, but the statement that “lifelong penicillin prophylaxis is recommended” is stronger than typical guideline language and may not be universally accepted.\n\nMinimal fix: Explicitly state that current institutional/consensus guidelines in this scenario recommend lifelong penicillin prophylaxis in addition to standard vaccination, or change the options so only one reasonable prophylactic approach remains.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed)\\nVerdict on keyed answer: Miskeyed – best defensible answer is amphotericin B monotherapy (A)\\n\\nKey stem clues: deferoxamine use, transfusional iron overload, cavitary RUL lesion, biopsy with broad, nonseptate, right-angle branching hyphae → rhinopulmonary mucormycosis in a high–iron state. Standard of care is to discontinue deferoxamine and start high-dose liposomal amphotericin B. Combination with iron chelators such as deferasirox is investigational/controversial and not established “optimal” therapy in guideline-based practice.\\n\\nLogical issues: The stem asks for “optimal antifungal combination therapy,” but contemporary guidelines (IDSA, ECMM) recommend liposomal amphotericin B as primary therapy; they do not endorse routine combination with deferasirox. Thus option A (liposomal amphotericin B alone) is the most guideline-consistent choice, while D asserts a nonstandard, research-level strategy as optimal yet is keyed as correct → miskey. Other options (B, C, E) are clearly inferior or second-line.\\n\\nMedical accuracy issues: Explanation overstates deferasirox’s role and outcome benefit; current evidence is limited and not practice standard.\\n\\nMinimal fix: Change the key to A and revise the explanation to emphasize amphotericin B monotherapy plus stopping deferoxamine as standard of care.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed)\nVerdict on keyed answer: Miskeyed – best defensible answer is amphotericin B monotherapy (A)\n\nKey stem clues: deferoxamine use, transfusional iron overload, cavitary RUL lesion, biopsy with broad, nonseptate, right-angle branching hyphae → rhinopulmonary mucormycosis in a high–iron state. Standard of care is to discontinue deferoxamine and start high-dose liposomal amphotericin B. Combination with iron chelators such as deferasirox is investigational/controversial and not established “optimal” therapy in guideline-based practice.\n\nLogical issues: The stem asks for “optimal antifungal combination therapy,” but contemporary guidelines (IDSA, ECMM) recommend liposomal amphotericin B as primary therapy; they do not endorse routine combination with deferasirox. Thus option A (liposomal amphotericin B alone) is the most guideline-consistent choice, while D asserts a nonstandard, research-level strategy as optimal yet is keyed as correct → miskey. Other options (B, C, E) are clearly inferior or second-line.\n\nMedical accuracy issues: Explanation overstates deferasirox’s role and outcome benefit; current evidence is limited and not practice standard.\n\nMinimal fix: Change the key to A and revise the explanation to emphasize amphotericin B monotherapy plus stopping deferoxamine as standard of care.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Older woman, high‑grade serous ovarian cancer, subacute cerebellar ataxia/dysarthria/nystagmus, high‑titer anti‑Yo antibodies in serum and CSF, CSF lymphocytic pleocytosis. This is classic paraneoplastic cerebellar degeneration due to anti‑Yo. The question asks for an “immunotherapy protocol,” implying first‑line disease‑modifying treatment beyond tumor control.\\n\\nAnti‑Yo–associated paraneoplastic cerebellar degeneration is notoriously refractory to therapy; among immunotherapies, cytotoxic agents such as cyclophosphamide plus corticosteroids are commonly recommended to attempt stabilization, particularly early. Option C (monthly cyclophosphamide 750 mg/m² plus prednisone) is therefore the most defensible protocol given the answer explanation. High‑dose IV methylprednisolone alone (A) or IVIG alone (B) are less favored and often ineffective in anti‑Yo. Rituximab (D) has less evidence in anti‑Yo specifically, and the stem emphasizes plasma cell depletion and CNS penetration, favoring cyclophosphamide. Tumor surgery alone (E) is inadequate.\\n\\nMain medical/logical issues: Minor—no universally established “standard” exists and evidence is limited, but C is still most defensible among listed options. \\n\\nMinimal fix: Clarify in stem that “Among the following, which is the most evidence‑supported immunotherapy regimen to attempt stabilization of anti‑Yo paraneoplastic cerebellar degeneration?”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Older woman, high‑grade serous ovarian cancer, subacute cerebellar ataxia/dysarthria/nystagmus, high‑titer anti‑Yo antibodies in serum and CSF, CSF lymphocytic pleocytosis. This is classic paraneoplastic cerebellar degeneration due to anti‑Yo. The question asks for an “immunotherapy protocol,” implying first‑line disease‑modifying treatment beyond tumor control.\n\nAnti‑Yo–associated paraneoplastic cerebellar degeneration is notoriously refractory to therapy; among immunotherapies, cytotoxic agents such as cyclophosphamide plus corticosteroids are commonly recommended to attempt stabilization, particularly early. Option C (monthly cyclophosphamide 750 mg/m² plus prednisone) is therefore the most defensible protocol given the answer explanation. High‑dose IV methylprednisolone alone (A) or IVIG alone (B) are less favored and often ineffective in anti‑Yo. Rituximab (D) has less evidence in anti‑Yo specifically, and the stem emphasizes plasma cell depletion and CNS penetration, favoring cyclophosphamide. Tumor surgery alone (E) is inadequate.\n\nMain medical/logical issues: Minor—no universally established “standard” exists and evidence is limited, but C is still most defensible among listed options. \n\nMinimal fix: Clarify in stem that “Among the following, which is the most evidence‑supported immunotherapy regimen to attempt stabilization of anti‑Yo paraneoplastic cerebellar degeneration?”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent allopurinol initiation (3 weeks), fever, facial edema, diffuse erythematous rash over 60% BSA, marked eosinophilia, atypical lymphocytes, and severe hepatitis (AST 850, ALT 620) are classic for DRESS syndrome with visceral involvement. This constellation supports need for systemic corticosteroids with a prolonged taper to prevent relapse, particularly of hepatitis.\\nEvaluation of options: A (1 mg/kg PO taper over 2 weeks) uses appropriate dose but taper is too short for severe DRESS with hepatitis; high risk of rebound, so inferior. B (IV methylprednisolone 1–2 mg/kg with slow 8–12 week taper) matches common expert recommendations for severe organ involvement and aligns with the explanation. C (1 g IV x3 days only) pulse monotherapy is inadequate; no taper. D (no steroids) is inappropriate with significant organ involvement. E (topical triamcinolone) is far insufficient for systemic disease.\\nMedical accuracy: The pathophysiology and management of DRESS, including need for systemic steroids and prolonged taper in severe hepatic involvement, are in line with contemporary expert consensus, acknowledging some practice variability.\\nMinimal fix: Explicitly state “severe hepatitis due to DRESS” in the stem and include discontinuation of allopurinol to reinforce causative drug withdrawal as part of management.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent allopurinol initiation (3 weeks), fever, facial edema, diffuse erythematous rash over 60% BSA, marked eosinophilia, atypical lymphocytes, and severe hepatitis (AST 850, ALT 620) are classic for DRESS syndrome with visceral involvement. This constellation supports need for systemic corticosteroids with a prolonged taper to prevent relapse, particularly of hepatitis.\nEvaluation of options: A (1 mg/kg PO taper over 2 weeks) uses appropriate dose but taper is too short for severe DRESS with hepatitis; high risk of rebound, so inferior. B (IV methylprednisolone 1–2 mg/kg with slow 8–12 week taper) matches common expert recommendations for severe organ involvement and aligns with the explanation. C (1 g IV x3 days only) pulse monotherapy is inadequate; no taper. D (no steroids) is inappropriate with significant organ involvement. E (topical triamcinolone) is far insufficient for systemic disease.\nMedical accuracy: The pathophysiology and management of DRESS, including need for systemic steroids and prolonged taper in severe hepatic involvement, are in line with contemporary expert consensus, acknowledging some practice variability.\nMinimal fix: Explicitly state “severe hepatitis due to DRESS” in the stem and include discontinuation of allopurinol to reinforce causative drug withdrawal as part of management.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]